Sickle Cell Anemia Treatments

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	**DD** – Drug-Drug Interaction	**MD** – Maximum Dose Limit	**TD** - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	**DS** – Maximum Days' Supply Allowed	**PR** – Enrollment in a Physician-Supervised Program Required	**UN** – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	**DT** – Duration of Therapy Limit	**PU** – Prior Use of Other Medication is Required	**X** – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	**DX** – Diagnosis Code Requirement	**QL** – Quantity Limit	**YQ** – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	**ER** – Early Refill	**RX** – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS
Aetna Better Health of Louisiana **1-855-242-0802**
AmeriHealth Caritas Louisiana **1-800-684-5502**
Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**
Healthy Blue **1-844-521-6942**
Louisiana Healthcare Connections **1-888-929-3790**
UnitedHealthcare **1-800-310-6826**

Sickle Cell Anemia Treatments

POS Edits
CL – Additional clinical information (age, diagnosis, prescriber specialty, etc.) is required for crizanlizumab-tmca (Adakveo®), L-glutamine (Endari™), and voxelotor (Oxbryta®).
~~**QL** – Pharmacy claims for voxelotor (Oxbryta®) are limited to a quantity of 90 tablets per 30 days.~~

Revision / Date	Implementation Date
Created POS Document	November 2020
Removed quantity limit for Oxbryta® / January 2022	July 2022